GSK cuts 24-va­lent pneu­mo­coc­cal pro­gram for adults due to com­pe­ti­tion

GSK is set­ting aside a mid-stage 24-va­lent pneu­mo­coc­cal vac­cine pro­gram for adults to in­stead fo­cus on a pre­clin­i­cal op­tion that cov­ers 30-plus va­lents, the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA